LISATA THERAPEUTICS, INC. (LSTA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 15M 30M 45M FY16: 35.3M FY22: 0 FY23: 0 FY24: 1M FY25: 170K FY16 FY22 FY23 FY24 FY25

Gross Profit Annual

0 7M 14M 21M FY10: 20.2M FY11: 1.4M FY12: 2.4M FY13: 1.7M FY10 FY11 FY12 FY13

Operating Income Annual

-60M -40M -20M 0 20M 40M 60M FY21: -29.1M FY22: -57.6M FY23: -25.7M FY24: -22.4M FY25: -18.2M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-60M -40M -20M 0 20M 40M 60M FY21: -27.5M FY22: -54.2M FY23: -20.8M FY24: -20M FY25: -16.6M FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 15M 30M 45M FY12: 11.9M FY13: 12.9M FY14: 15.7M FY15: 20.2M FY16: 31.1M FY12 FY13 FY14 FY15 FY16

Operating Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY21: -22.2M FY22: -21.2M FY23: -20M FY24: -19.4M FY25: -15.9M FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY21: -22.3M FY22: -21.5M FY23: -20M FY24: -19.4M FY25: -16M FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 3M 6M 9M FY21: 3.7M FY22: 5.2M FY23: 8.1M FY24: 8.3M FY25: 8.7M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '21: -2.37 Q4 '21: -3.72 Q1 '22: -4.58 Q2 '22: -6.12 Q3 '22: -12.26 Q4 '22: -10.47 Q1 '23: -10.19 Q2 '23: -9.05 Q3 '23: -1.82 Q4 '23: -2.58 Q1 '24: -2.46 Q2 '24: -2.57 Q3 '24: -2.51 Q4 '24: -2.40 Q1 '25: -2.30 Q2 '25: -2.23 Q3 '25: -2.13 Q4 '25: -1.91 Q1 '26: -1.86 Q2 '26: -1.64 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.